Fig.3From: Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case–control studyMortality in two treatment groups in the matched population. A All-cause in-hospital mortality; (B) VAP-related in-hospital mortality. IH + IV, inhaled plus intravenous; IV, intravenous. Day 0 represent VAP onsetBack to article page